Iakhontova O I, Dudanova O P
Vrach Delo. 1990 May(5):18-20.
Hepatoprotectors were used in 89 patients with chronic liver diseases from 1 to 6 months. A positive clinico-biochemical and immunological effect, namely, increase of the T-lymphocyte count, normalization of the ratio of immunoregulator cells, reduction of the antibody-dependent cellular toxicity, level of circulating immune complexes, immunoglobulins. Patients with chronic persisting hepatitis showed a stable remission from 6 to 12 months. Despite prolonged treatment, patients with active chronic hepatitis and liver cirrhosis developed exacerbation of the disease that was in 2/3 of patients caused by an increase of deficit of theophyllin-sensitive lymphocytes-suppressors and in 1/3 by K-cell deficit. The necessity is emphasized of interrupted treatment with hepatoprotectors for not less that 2-3 months alternating hepatoprotectors with immunomodulators.
89例慢性肝病患者使用了保肝药物1至6个月。产生了积极的临床生化和免疫学效果，即T淋巴细胞计数增加、免疫调节细胞比例正常化、抗体依赖性细胞毒性、循环免疫复合物水平、免疫球蛋白降低。慢性持续性肝炎患者出现了6至12个月的稳定缓解。尽管进行了长期治疗，但活动性慢性肝炎和肝硬化患者仍出现疾病恶化，其中三分之二的患者是由于茶碱敏感淋巴细胞抑制因子缺乏增加所致，三分之一是由于K细胞缺乏所致。强调了保肝药物间断治疗不少于2至3个月的必要性，将保肝药物与免疫调节剂交替使用。
